FR2737500B1 - Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques - Google Patents

Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques

Info

Publication number
FR2737500B1
FR2737500B1 FR9509643A FR9509643A FR2737500B1 FR 2737500 B1 FR2737500 B1 FR 2737500B1 FR 9509643 A FR9509643 A FR 9509643A FR 9509643 A FR9509643 A FR 9509643A FR 2737500 B1 FR2737500 B1 FR 2737500B1
Authority
FR
France
Prior art keywords
sequence
sequences
pol
partial
complete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9509643A
Other languages
English (en)
French (fr)
Other versions
FR2737500A1 (fr
Inventor
Herve Perron
Frederic Beseme
Frederic Bedin
Baccala Glaucia Paranhos
Pradel Florence Komurian
Reynaud Colette Jolivet
Bernard Mandrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Original Assignee
Biomerieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9509643A priority Critical patent/FR2737500B1/fr
Application filed by Biomerieux SA filed Critical Biomerieux SA
Priority to AT07018564T priority patent/ATE541933T1/de
Priority to PL96319512A priority patent/PL319512A1/xx
Priority to CA2201282A priority patent/CA2201282C/fr
Priority to ES96420265T priority patent/ES2293645T3/es
Priority to ES07018564T priority patent/ES2379011T3/es
Priority to JP50817997A priority patent/JP4444372B2/ja
Priority to EP07018564A priority patent/EP1916304B1/fr
Priority to PCT/FR1996/001244 priority patent/WO1997006260A1/fr
Priority to EP96420265A priority patent/EP0789077B1/fr
Priority to SK567-97A priority patent/SK56797A3/sk
Priority to CZ971357A priority patent/CZ135797A3/cs
Priority to DE69637264T priority patent/DE69637264T2/de
Priority to US08/691,563 priority patent/US6001987A/en
Priority to HU9900425A priority patent/HUP9900425A3/hu
Priority to AU68232/96A priority patent/AU730080B2/en
Priority to AT96420265T priority patent/ATE374252T1/de
Priority to BR9606566A priority patent/BR9606566A/pt
Publication of FR2737500A1 publication Critical patent/FR2737500A1/fr
Priority to BG101355A priority patent/BG62977B1/bg
Priority to IS4455A priority patent/IS4455A/is
Priority to NZ316080A priority patent/NZ316080A/en
Priority to NO971493A priority patent/NO971493L/no
Application granted granted Critical
Publication of FR2737500B1 publication Critical patent/FR2737500B1/fr
Priority to US09/374,766 priority patent/US6579526B1/en
Priority to US10/430,442 priority patent/US20030186391A1/en
Priority to US11/463,109 priority patent/US7932350B2/en
Priority to JP2009265658A priority patent/JP5143814B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
FR9509643A 1995-08-03 1995-08-03 Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques Expired - Fee Related FR2737500B1 (fr)

Priority Applications (26)

Application Number Priority Date Filing Date Title
FR9509643A FR2737500B1 (fr) 1995-08-03 1995-08-03 Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
AU68232/96A AU730080B2 (en) 1995-08-03 1996-08-02 Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
CA2201282A CA2201282C (fr) 1995-08-03 1996-08-02 Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
ES96420265T ES2293645T3 (es) 1995-08-03 1996-08-02 Material virico y fragmentos nucleotidicos asociados con la enclerosis en placas, con fines de diagnostico, profilacticos y terapeuticos.
ES07018564T ES2379011T3 (es) 1995-08-03 1996-08-02 Polipéptidos antigénicos asociados a la esclerosis en placas y utilizaciones
JP50817997A JP4444372B2 (ja) 1995-08-03 1996-08-02 診断、予防および治療のための多発性硬化症に関与するウイルス性物質およびヌクレオチドフラグメント
EP07018564A EP1916304B1 (fr) 1995-08-03 1996-08-02 Polypeptides antigéniques associés à la sclérose en plaques et utilisations
PCT/FR1996/001244 WO1997006260A1 (fr) 1995-08-03 1996-08-02 Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
EP96420265A EP0789077B1 (fr) 1995-08-03 1996-08-02 Matériel viral et fragments nucléotidiques associés à la sclérose en plaques, à des fins de diagnostic, prophylactiques et thérapeutiques
SK567-97A SK56797A3 (en) 1995-08-03 1996-08-02 Viral material and nucleotide fragments associated with multiple sclerosis useful for diagnostic, preventive and therapeutic purposes
CZ971357A CZ135797A3 (cs) 1995-08-03 1996-08-02 Virový materiál a nukleotidové fragmenty asociované s roztroušenou sklerozou užitečné pro diagnostické, preventivní a terapeutické účely
DE69637264T DE69637264T2 (de) 1995-08-03 1996-08-02 Virales Material und Multiple-Sklerose assoziierte Nukleotidfragmente mit diagnostischen, prophylaktischen und therapeutischen Verwendungen
US08/691,563 US6001987A (en) 1995-08-03 1996-08-02 Isolated nucleotide sequences associated with Multiple sclerosis
HU9900425A HUP9900425A3 (en) 1995-08-03 1996-08-02 Viral material and nucleotide fragments associated with multiple sclerosis useful for diagnostic, preventive and therapeutic purposes
AT07018564T ATE541933T1 (de) 1995-08-03 1996-08-02 Antigene polypeptide, die mit multipler sklerose assoziiert sind, und verwendungszwecke
AT96420265T ATE374252T1 (de) 1995-08-03 1996-08-02 Virales material und multiple-sklerose assoziierte nukleotidfragmente mit diagnostischen,prophylaktischen und therapeutischen verwendungen
PL96319512A PL319512A1 (en) 1995-08-03 1996-08-02 Viral material and nucleotidic fragments associated with sclerosis multiplex or diagnostic, prophylactic and therapeutic purposes
BR9606566A BR9606566A (pt) 1995-08-03 1996-08-02 Material viral no estado isolado ou purificado fragmento de nicliotideos sonda nucleica de detecção de um agente patógeno e/ou infeccioso iniciador para a amplificação por polimerização de uma rna ou um dna de material viral rna ou dna e notadamente vetor de replicação peptideo anticorpo mono- ou policlonal reativo de detecção de virus-1 ou de uma exposição do referido virus composição diagnóstica profilática ou terapéutica processos para detectar um agente patológico e/ou infeccioso e a presenç
BG101355A BG62977B1 (bg) 1995-08-03 1997-03-25 Вирусен материал и нуклеотидни фрагменти, свързани с диагностика, профилактика и лечение на мултиплената склероза
IS4455A IS4455A (is) 1995-08-03 1997-03-26 Veiruefni og kirnisbrot tengd MS sjúkdómi sem nýta má til sjúkdómsgreiningar, hindrunar og lækningar
NZ316080A NZ316080A (en) 1995-08-03 1997-03-27 Viral material and nucleotide fragments associated with multiple sclerosis retrovirus useful for diagnostic, preventive and therapeutic
NO971493A NO971493L (no) 1995-08-03 1997-04-02 Virusmateriale og nukleotidfragmenter som er forbundet med multippel sklerose, og som kan anvendes til diagnostiske, preventive og terapeutiske formål
US09/374,766 US6579526B1 (en) 1995-08-03 1999-08-16 Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
US10/430,442 US20030186391A1 (en) 1995-08-03 2003-05-07 Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purpose
US11/463,109 US7932350B2 (en) 1995-08-03 2006-08-08 Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
JP2009265658A JP5143814B2 (ja) 1995-08-03 2009-11-20 診断、予防および治療のための多発性硬化症に関与するウイルス性物質およびヌクレオチドフラグメント

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9509643A FR2737500B1 (fr) 1995-08-03 1995-08-03 Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques

Publications (2)

Publication Number Publication Date
FR2737500A1 FR2737500A1 (fr) 1997-02-07
FR2737500B1 true FR2737500B1 (fr) 1997-08-29

Family

ID=9481811

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9509643A Expired - Fee Related FR2737500B1 (fr) 1995-08-03 1995-08-03 Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques

Country Status (19)

Country Link
US (4) US6001987A (enExample)
EP (2) EP1916304B1 (enExample)
JP (2) JP4444372B2 (enExample)
AT (2) ATE374252T1 (enExample)
AU (1) AU730080B2 (enExample)
BG (1) BG62977B1 (enExample)
BR (1) BR9606566A (enExample)
CA (1) CA2201282C (enExample)
CZ (1) CZ135797A3 (enExample)
DE (1) DE69637264T2 (enExample)
ES (2) ES2293645T3 (enExample)
FR (1) FR2737500B1 (enExample)
HU (1) HUP9900425A3 (enExample)
IS (1) IS4455A (enExample)
NO (1) NO971493L (enExample)
NZ (1) NZ316080A (enExample)
PL (1) PL319512A1 (enExample)
SK (1) SK56797A3 (enExample)
WO (1) WO1997006260A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2737500B1 (fr) * 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
EP0938320B2 (en) * 1996-03-26 2014-06-18 Michael S. Kopreski Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
WO1998014617A1 (en) * 1996-10-04 1998-04-09 Chronix Biomedical Diagnostic detection of nucleic acids
JP4226657B2 (ja) 1996-11-26 2009-02-18 ベーイーオー メリュー 診断、予防、及び治療のための、多発性硬化症に関連するウイルス性物質及びヌクレオチド断片
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
FR2762601B3 (fr) 1997-04-29 1999-06-04 Bio Merieux Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utilisations
FR2762600B1 (fr) * 1997-04-29 1999-11-05 Bio Merieux Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utlisations
US20040176314A1 (en) * 1997-07-07 2004-09-09 Bio Merieux Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders
FR2765588A1 (fr) * 1997-07-07 1999-01-08 Bio Merieux Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques
CA2298834C (fr) * 1997-07-07 2015-03-10 Bio Merieux Sequences retroviraux endogenes, associees a des maladies auto-immunes et/ou a des perturbations de la grossesse
JP2002511277A (ja) * 1998-04-08 2002-04-16 エムエス・リサーチ・アクティーゼルスカブ 多発性硬化症および他の脱髄性疾患の診断
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
US20090233276A1 (en) * 1998-09-22 2009-09-17 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
FR2788784A1 (fr) * 1999-01-21 2000-07-28 Bio Merieux Fragment nucleique endogene associe a une maladie auto-immune, procede de marquage et reactif
EP1029917A1 (en) * 1999-02-15 2000-08-23 Bio Merieux The LTR region of MSRV-1 and the proteins it encodes, and probes and methods for detecting MSRV-1 retrovirus
WO2001014564A2 (en) * 1999-08-20 2001-03-01 Curagen Corporation Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby
DE10012875B4 (de) * 2000-03-16 2004-04-01 Infineon Technologies Ag Mobilfunkempfänger
EP1265989A2 (en) * 2000-03-21 2002-12-18 MS Research A/S An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
DE60239470D1 (de) * 2001-07-25 2011-04-28 Oncomedx Inc Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
US8680065B2 (en) * 2008-09-11 2014-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oligonucleotides of human endogenous retrovirus 9 (ERV-9) long terminal repeat (LTR) and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1133829A (en) * 1978-08-24 1982-10-19 Neil J.L. Gilmour Pasteurellosis vaccines
US4311686A (en) * 1979-04-30 1982-01-19 The Immunology Development Corporation Methodology for the immunodiagnosis of multiple sclerosis and/or malignant diseases from blood sample analysis
US4396600A (en) * 1980-12-18 1983-08-02 Gus Gallucci Adult schistosome worm-derived antigenic substance and method of obtaining same
US4388298A (en) * 1982-07-14 1983-06-14 The United States Of America As Represented By The Secretary Of Agriculture Propagation of hemorrhagic enteritis virus in a turkey cell line and vaccine produced
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
US4647773A (en) * 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
NZ218050A (en) * 1985-11-13 1989-05-29 Wistar Inst Test for the presence of htlv-1v
US4900553A (en) * 1987-09-11 1990-02-13 Case Western Reserve University Method of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
EP0326395A2 (en) * 1988-01-29 1989-08-02 City Of Hope Method of detecting and identifying certain viral sequences
FR2651581B1 (fr) * 1989-09-06 1994-05-13 Centre Nal Recherc Scientifique Moyens pour le diagnostic de neuropathies demyelinisantes, en particulier de la sclerose en plaques.
US5219837A (en) * 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5158976A (en) * 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
WO1992015672A1 (en) * 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
DK173091D0 (da) * 1991-10-11 1991-10-11 Schleroseforeningen The Danish Biologisk materiale
FR2689520B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
FR2689521B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
JPH07508178A (ja) * 1992-05-18 1995-09-14 ジェネンテク，インコーポレイテッド レセプター活性化
GB9310657D0 (en) * 1993-05-24 1993-07-07 Univ London Retrovirus
US5580766A (en) * 1994-01-14 1996-12-03 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
ATE285475T1 (de) 1994-02-04 2005-01-15 Bio Merieux Msrv1 virus der mit multipler sklerose verbunden ist, seine nukleären bestandteile und verwendungen
US5691147A (en) * 1994-06-02 1997-11-25 Mitotix, Inc. CDK4 binding assay
US5710037A (en) * 1994-06-10 1998-01-20 The United States Of America As Represented By The Department Of Health And Human Services Retroviral vector particles
FR2731356B1 (fr) * 1995-03-09 1997-04-30 Bio Merieux Virus msrv-1 et agent pathogene et/ou infectant msrv-2 associes a la polyarthrite rhumatoide
FR2737500B1 (fr) * 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques

Also Published As

Publication number Publication date
US20070117189A1 (en) 2007-05-24
BR9606566A (pt) 1997-12-30
SK56797A3 (en) 1998-09-09
CZ135797A3 (cs) 1998-06-17
HUP9900425A2 (hu) 1999-05-28
US6579526B1 (en) 2003-06-17
CA2201282C (fr) 2013-04-02
AU730080B2 (en) 2001-02-22
JP4444372B2 (ja) 2010-03-31
ES2293645T3 (es) 2008-03-16
US20030186391A1 (en) 2003-10-02
EP1916304A2 (fr) 2008-04-30
JP2010047604A (ja) 2010-03-04
EP0789077B1 (fr) 2007-09-26
ES2379011T3 (es) 2012-04-19
EP1916304B1 (fr) 2012-01-18
EP1916304A3 (fr) 2008-05-07
ATE374252T1 (de) 2007-10-15
ATE541933T1 (de) 2012-02-15
DE69637264D1 (de) 2007-11-08
NO971493D0 (no) 1997-04-02
FR2737500A1 (fr) 1997-02-07
NO971493L (no) 1997-06-03
BG101355A (en) 1997-12-30
WO1997006260A1 (fr) 1997-02-20
PL319512A1 (en) 1997-08-18
BG62977B1 (bg) 2000-12-29
IS4455A (is) 1997-03-26
JPH11502416A (ja) 1999-03-02
DE69637264T2 (de) 2008-06-26
JP5143814B2 (ja) 2013-02-13
HUP9900425A3 (en) 1999-11-29
NZ316080A (en) 1999-04-29
US7932350B2 (en) 2011-04-26
AU6823296A (en) 1997-03-05
US6001987A (en) 1999-12-14
CA2201282A1 (fr) 1997-02-20
EP0789077A1 (fr) 1997-08-13

Similar Documents

Publication Publication Date Title
FR2737500B1 (fr) Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
Saltarelli et al. Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infectious virus
Ono et al. Nucleotide sequence of the Syrian hamster intracisternal A-particle gene: close evolutionary relationship of type A particle gene to types B and D oncovirus genes
JP2019522461A5 (enExample)
Mager et al. HERV-H endogenous retroviruses: presence in the New World branch but amplification in the Old World primate lineage
Buzdin et al. Friends-enemies: endogenous retroviruses are major transcriptional regulators of human DNA
USRE37918E1 (en) Nucleic acid derivatives
Böhnlein et al. Identification of a U5-specific sequence required for efficient polyadenylation within the human immunodeficiency virus long terminal repeat
Bangham et al. PCR analysis of DNA from multiple sclerosis patients for the presence of HTLV-I
ATE60800T1 (de) Klonierte dns-sequenzen, hybridisierbar mit genom-rns vom ''lymphadenopathy-associated virus (lav)''.
CA2062829A1 (fr) Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour lediagnostic in vitro des infections dues a ces virus
CA2154023A1 (en) Recombinant infectious non-segmented negative strand rna virus
Forster et al. Phylogenetic resolution of complex mutational features at Y-STR DYS390 in aboriginal Australians and Papuans.
US5580703A (en) Human adeno-associated virus integration site DNA and uses thereof
Rethwilm et al. Molecular cloning of the genome of human spumaretrovirus
Wachsman et al. HTLV x-gene product: requirement for the env methionine initiation codon
Mager Polyadenylation function and sequence variability of the long terminal repeats of the human endogenous retrovirus-like family RTVL-H
GASMI et al. Long terminal repeat sequence analysis of HTLV type I molecular variants identified in four north African patients
US5112767A (en) Vectors with enhancer domains
Chou et al. Preferred nucleotide sequence at the integration target site of human T‐cell leukemia virus type I from patients with adult T‐cell leukemia
Herrmann et al. PCR and reverse dot hybridization for the detection of endogenous retroviral transcripts
Haltmeier et al. Identification of S71-related human endogenous retroviral sequences with full-length pol genes
US20090061488A1 (en) Method of synthesizing a target polynucleotide encoding a protein
Walther et al. Molecular cloning of proviral DNA and structural analysis of the transduced myc oncogene of avian oncovirus CMII
Fang et al. Integration of HTLV-1 provirus into mouse transforming growth factor-α gene

Legal Events

Date Code Title Description
ST Notification of lapse